

Results of AGM and Issue of New Securities

Aurora Labs Limited (Aurora Labs or the "Company") is pleased to provide the results of its Annual General Meeting (AGM) held this morning.

In accordance with ASX listing rule 3.13.2 and Section 251 AA of the Corporations Act 2001, the details of the resolutions and the proxies received in respect of each resolution are as follows:

1. Adoption of Remuneration Report

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For	Against	Discretionary	Abstain/Excluded
7,296,282 87.6% in favor	194,895	833,865	25,020,961

The resolution was passed on a show of hands as an ordinary resolution.

2. Re-Election of Director – Mr Paul Kristensen

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For	Against	Discretionary	Abstain/Excluded
32,386,743 97.5% in favor	11,895	833,865	113,500

The resolution was passed on a show of hands as an ordinary resolution.

3. Re-election of Director – Mr Mel Ashton

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For	Against	Proxy's Discretion	Abstain/Excluded
32,336,743 97.5% in favor	11,895	833,865	163,500

The resolution was passed on a show of hands as an ordinary resolution.

4. Re-election of Director - Mr Mathew Whyte

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For	Against	Proxy's Discretion	Abstain/Excluded
32,386,743 97.5% in favor	11,895	833,865	113,500

The resolution was passed on a show of hands as an ordinary resolution.

5. Grant of Performance Rights to Director under Employee Incentive Plan – Mr David Budge

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For	Against	Proxy's Discretion	Abstain
6,811,582 81% in favor	768,520	833,865	24,932,036

The resolution was passed on a show of hands as an ordinary resolution.

For personal use only

6. Grant of Performance Rights to Director under Employee Incentive Plan – Mr John (Nathan) Henry

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For	Against	Proxy's Discretion	Abstain/Excluded
6,799,894 81% in favor	768,520	833,865	24,943,724

The resolution was passed on a show of hands as an ordinary resolution.

7. Grant of Performance Rights to Director under Employee Incentive Plan – Mr Paul Kristensen

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For	Against	Proxy's Discretion	Abstain/Excluded
7,074,082 84% in favor	506,020	833,865	24,932,036

The resolution was passed on a show of hands as an ordinary resolution.

8. Grant of Performance Rights to Director under Employee Incentive Plan – Mr Norman (Mel) Ashton

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For	Against	Proxy's Discretion	Abstain/Excluded
7,024,082 84% in favor	506,020	833,865	24,982,036

The resolution was passed on a show of hands as an ordinary resolution.

9. Grant of Performance Rights to Director under Employee Incentive Plan – Mr Mathew Whyte

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For	Against	Proxy's Discretion	Abstain/Excluded
7,069,082 84% in favor	506,020	838,865	24,932,036

The resolution was passed on a show of hands as an ordinary resolution.

10. Ratification of issue of Advisor options to Max capital Pty Ltd

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For	Against	Proxy's Discretion	Abstain/Excluded
32,006,418 96% in favor	479,720	863,865	21,000

The resolution was passed on a show of hands as an ordinary resolution.

For personal use only

11. Approval of Redemption and Cancellation of Class B Performance Shares

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For	Against	Proxy's Discretion	Abstain/Excluded
7,385,607 88% in favor	170,395	838,865	24,951,136

The resolution was passed on a show of hands as a special resolution.

12. Approval of issue of Securities under amended Employee Incentive Plan

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For	Against	Proxy's Discretion	Abstain/Excluded
7,223,607 86% in favor	332,395	838,865	24,951,136

The resolution was passed on a show of hands as an ordinary resolution.

13. Approval of Additional Placement Facility

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For	Against	Proxy's Discretion	Abstain/Excluded
32,231,918 97% in favor	253,020	838,865	22,200

The resolution was passed on a show of hands as a special resolution.

Issue of new securities

The Company also provides the following in relation to the issue of unquoted Performance Rights as approved by Shareholders pursuant to Resolution 5,6,7,8 and 9 above:

1. Appendix 3B – New Issue Announcement;
2. Appendix 3Y – Change of Directors Interest Notice for Mr David Budge;
3. Appendix 3Y – Change of Directors Interest Notice for Mr John Nathan Henry;
4. Appendix 3y – Change of Directors Interest Notice for Mr Paul Kristensen;
5. Appendix 3y – Change of Directors Interest Notice for Mr Mel Ashton; and
6. Appendix 3Y – Change of Directors Interest Notice for Mr Mathew Whyte.

For further information please contact:

enquiries@auroralabs3D.com

For personal use only

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12

Name of entity

Aurora Labs Limited

ABN

44 601 164 505

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

- | | | |
|---|--|---|
| 1 | +Class of +securities issued or to be issued | Unquoted Performance Rights (Performance Rights) |
| 2 | Number of +securities issued or to be issued (if known) or maximum number which may be issued | 250,000 |
| 3 | Principal terms of the +securities (eg, if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion) | <p>The Performance Rights have been granted under the Company's Employee Incentive Plan (EIP) for no consideration, and no amount is payable on the vesting or exercising of the Performance Rights.</p> <p>Each Performance Right entitles the holder to subscribe for one (1) fully paid ordinary share in the Company, for nil cash consideration subject to EIP Rules.</p> <p>Each Performance Right will only vest and become exercisable following the satisfaction of the Performance Condition and Vesting Condition.</p> <p>Each Performance Right is subject to a Performance Condition that the 10-day</p> |

For personal use only

volume weighted average market price (as defined in the ASX Listing Rules) of the Company's quoted Shares first exceeds \$0.90 per Share.

Each Performance Right is subject to a Vesting Condition that the holder achieves a minimum of 12 months continuous service with the Company.

Each Performance Right not vested or exercised will expire on 31 January 2023 at 5.00pm (WST).

(Refer to Annexure "B" for full Terms and Conditions of Performance Rights)

4 Do the +securities rank equally in all respects from the date of allotment with an existing +class of quoted +securities?

If the additional securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

Performance Rights – No

The granting of a Performance Right does not give the holder a legal or beneficial interest in a fully paid ordinary share until the Performance Right vests and are exercised. When the Performance Rights have been exercised, ordinary shares will be issued and these shares will then rank equally with existing shares.

5 Issue price or consideration

Nil

6 Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)

Performance rights issued to related parties as remuneration pursuant to the Employee incentive Plan and following shareholder approval at the AGM held on 30 November 2018

6a Is the entity an +eligible entity that has obtained security holder approval under rule 7.1A?

Yes

+ See chapter 19 for defined terms.

	If Yes, complete sections 6b – 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i							
6b	The date the security holder resolution under rule 7.1A was passed	30 November 2018						
6c	Number of +securities issued without security holder approval under rule 7.1	Not applicable						
6d	Number of +securities issued with security holder approval under rule 7.1A	Not applicable						
6e	Number of +securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	250,000 Performance Rights approved at AGM held 30 November 2018.						
6f	Number of securities issued under an exception in rule 7.2	Not applicable						
6g	If securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the issue date and both values. Include the source of the VWAP calculation.	Not applicable.						
6h	If securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	Not applicable.						
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	LR 7.1: 10,022,690 LR 7.1A: 6,888,591						
7	Dates of entering +securities into uncertificated holdings or despatch of certificates	30 November 2018						
8	Number and +class of all +securities quoted on ASX	<table border="1"> <thead> <tr> <th>Number</th> <th>+Class</th> </tr> </thead> <tbody> <tr> <td>68,946,104</td> <td>Ordinary shares</td> </tr> <tr> <td>3,686,000</td> <td>Options exercisable at</td> </tr> </tbody> </table>	Number	+Class	68,946,104	Ordinary shares	3,686,000	Options exercisable at
Number	+Class							
68,946,104	Ordinary shares							
3,686,000	Options exercisable at							

(including the securities in section 2 if applicable)	\$1.00 & Expiry 17/4/2020
---	---------------------------

	Number	+Class
9	6,536,092	Unquoted Options Exercisable at \$0.20 Expiring 31/12/2018 (A3DAH)
	250,000	Unquoted Options Exercisable at \$0.50 Expiring 31/12/2020 (A3DAI)
	480,000	Unquoted Options Exercisable at \$2.23 Expiring 30/11/2019 (A3DAI)
	931,000	Unquoted Options Exercisable at \$3.00 Expiring 31/03/2020 (A3DAI)
	40,000	Unquoted Options Exercisable at \$1.17 Expiring 30/06/2020 (A3DAI)
	462,000	Unquoted Options Exercisable at \$0.79 Expiring 31/08/2020 (A3DAI)
	50,000	Unquoted Options Exercisable at \$0.72 Expiring 30/09/2020 (A3DAI)
	100,000	Unquoted Options Exercisable at \$0.95 Expiring 31/07/2020 (A3DAI)
	200,000	Unquoted Options Exercisable at \$1.08 Expiring 31/01/2021 (A3DAI)
	7,612,500	Class C Performance Shares (A3DAI):
	867,159	Performance Rights expiring 31/01/2023

+ See chapter 19 for defined terms.

For personal use only

10 Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

Part 2 - Bonus issue or pro rata issue

11 Is security holder approval required?

12 Is the issue renounceable or non-renounceable?

13 Ratio in which the ⁺securities will be offered

14 ⁺Class of ⁺securities to which the offer relates

15 ⁺Record date to determine entitlements

16 Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?

17 Policy for deciding entitlements in relation to fractions

18 Names of countries in which the entity has ⁺security holders who will not be sent new issue documents
Note: Security holders must be told how their entitlements are to be dealt with.
Cross reference: rule 7.7.

19 Closing date for receipt of acceptances or renunciations

20 Names of any underwriters

21 Amount of any underwriting fee or commission

22 Names of any brokers to the issue

23	Fee or commission payable to the broker to the issue	Not applicable.
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of +security holders	Not applicable.
25	If the issue is contingent on +security holders' approval, the date of the meeting	Not applicable.
26	Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled	Not applicable.
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	Not applicable.
28	Date rights trading will begin (if applicable)	Not applicable.
29	Date rights trading will end (if applicable)	Not applicable.
30	How do +security holders sell their entitlements <i>in full</i> through a broker?	Not applicable.
31	How do +security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	Not applicable.
32	How do +security holders dispose of their entitlements (except by sale through a broker)?	Not applicable.
33	+Despatch date	Not applicable.

+ See chapter 19 for defined terms.

Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

34 Type of securities
(tick one)

(a) Securities described in **Part 1**

(b) All other securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

35 If the +securities are +equity securities, the names of the 20 largest holders of the additional +securities, and the number and percentage of additional +securities held by those holders

36 If the +securities are +equity securities, a distribution schedule of the additional +securities setting out the number of holders in the categories
1 - 1,000
1,001 - 5,000
5,001 - 10,000
10,001 - 100,000
100,001 and over

37 A copy of any trust deed for the additional +securities

Entities that have ticked box 34(b)

38 Number of securities for which +quotation is sought Not applicable.

39 Class of +securities for which quotation is sought Not applicable.

40 Do the +securities rank equally in all respects from the date of allotment with an existing +class of quoted +securities?

Not applicable.

If the additional securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

41 Reason for request for quotation now Not applicable.

Example: In the case of restricted securities, end of restriction period

(if issued upon conversion of another security, clearly identify that other security)

	Number	+Class
42 Number and +class of all +securities quoted on ASX (including the securities in clause 38)	Not applicable.	

+ See chapter 19 for defined terms.

For personal use only

Quotation agreement

1 +Quotation of our additional +securities is in ASX's absolute discretion. ASX may quote the +securities on any conditions it decides.

2 We warrant the following to ASX.

- The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
- There is no reason why those +securities should not be granted +quotation.
- An offer of the +securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that no-one has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.
- If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.

3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.

4 We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: 
 (Director & Company Secretary)

Date: 30 November 2018

Print name: Mathew Whyte

== == == == ==

+ See chapter 19 for defined terms.

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12

Part 1

Rule 7.1 – Issues exceeding 15% of capital	
Step 1: Calculate “A”, the base figure from which the placement capacity is calculated	
Insert number of fully paid ordinary securities on issue 12 months before date of issue or agreement to issue	58,457,575
<p>Add the following:</p> <ul style="list-style-type: none"> • Number of fully paid ordinary securities issued in that 12 month period under an exception in rule 7.2 • Number of fully paid ordinary securities issued in that 12 month period with shareholder approval • Number of partly paid ordinary securities that became fully paid in that 12 month period <p><i>Note:</i></p> <ul style="list-style-type: none"> • <i>Include only ordinary securities here – other classes of equity securities cannot be added</i> • <i>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</i> • <i>It may be useful to set out issues of securities on different dates as separate line items</i> 	<ul style="list-style-type: none"> • 125,000 (Shares issued on 19/12/2017) • 354,500 (Shares issued on 02/03/2018) • 10,000 (Shares issued on 17/04/2018) • 245,000 (Shares issued on 12/07/2018) • 2,158,500 (Shares issued on 8/10/2018) • 880,000 (Shares issued on 31/10/2018) on exercise of Options (LR 7.2 exception 4) • 6,250,000 (Shares issued under placement on 02/03/2018 ratified at EGM held on 17/4/2018); and • 122,000 (Shares issued under SPP on 17/04/2018 ratified at EGM held on 17/04/2018)
Subtract the number of fully paid ordinary securities cancelled during that 12 month period	Nil
“A”	68,885,908

+ See chapter 19 for defined terms.

For personal use only

Step 2: Calculate 15% of “A”	
“B”	[Note: this value cannot be changed]
Multiply “A” by 0.15	10,332,886
Step 3: Calculate “C”, the amount of placement capacity under rule 7.1 that has already been used	
<p>Insert number of equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:</p> <ul style="list-style-type: none"> • Under an exception in rule 7.2 • Under rule 7.1A • With security holder approval under rule 7.1 or rule 7.4 <p><i>Note:</i></p> <ul style="list-style-type: none"> • This applies to equity securities, unless specifically excluded – not just ordinary securities • Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed • It may be useful to set out issues of securities on different dates as separate line items 	<ul style="list-style-type: none"> •35,196 (shares issued on 19/12/2017) •25,000 (shares issued on 30/08/2018) •250,000 (Advisor Options issued on 30/08/2018)
“C”	310,196
Step 4: Subtract “C” from [“A” x “B”] to calculate remaining placement capacity under rule 7.1	
“A” x 0.15 <i>Note: number must be same as shown in Step 2</i>	10,332,886
Subtract “C” <i>Note: number must be same as shown in Step 3</i>	310,196
Total [“A” x 0.15] – “C”	10,022,690 [Note: this is the remaining placement capacity under rule 7.1]

+ See chapter 19 for defined terms.

Part 2

Rule 7.1A – Additional placement capacity for eligible entities	
Step 1: Calculate “A”, the base figure from which the placement capacity is calculated	
“A” <i>Note: number must be same as shown in Step 1 of Part 1</i>	68,885,908
Step 2: Calculate 10% of “A”	
“D”	<i>Note: this value cannot be changed</i>
Multiply “A” by 0.10	6,888,591
Step 3: Calculate “E”, the amount of placement capacity under rule 7.1A that has already been used	
Insert number of equity securities issued or agreed to be issued in that 12- month period under rule 7.1A Notes: <ul style="list-style-type: none"> • <i>This applies to equity securities – not just ordinary securities</i> • <i>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</i> • <i>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</i> • <i>It may be useful to set out issues of securities on different dates as separate line items</i> 	Nil
“E”	Nil

+ See chapter 19 for defined terms.

For personal use only

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A	
"A" x 0.10 <i>Note: number must be same as shown in Step 2</i>	6,888,591
Subtract "E" <i>Note: number must be same as shown in Step 3</i>	Nil
Total ["A" x 0.10] – "E"	6,888,591 <i>Note: this is the remaining placement capacity under rule 7.1A</i>

+ See chapter 19 for defined terms.



Annexure “B” – Terms of Performance Rights

The terms and conditions of the Performance Rights are set out below. These terms are subject to, and should be read in accordance with, the Plan Rules.

1. Entitlement

Each Performance Right entitles the holder to subscribe for one fully paid ordinary share in the Company, for nil cash consideration, subject to these terms and conditions and pursuant to the Plan Rules.

2. Nil cash consideration

The Performance Rights will be granted for nil cash consideration.

3. Vesting

Each Performance Right will only vest and become exercisable following the satisfaction of the Performance Condition and Vesting Condition specified in the Offer.

Performance Condition: That the 10 day VWAP of Shares exceeds \$0.90 per Share on a date that is after the date the Performance Rights are granted.

Vesting Condition: That the holder achieve a minimum of 12 months continuous service with the Company from the date on which the holder was originally engaged by the Company.

4. Lapse

Each Performance Right will automatically lapse and may no longer be exercised on the End Date specified in the Offer.

5. Exercise

Vested Performance Rights may only be exercised by notice in writing to the Company (**Notice of Exercise**).

Any Notice of Exercise for a Performance Right received by the Company will be deemed to be a notice of the exercise of the Performance Rights specified in that notice as at the date of receipt. Performance Rights may only be exercised in multiples of 500 unless fewer than 500 Performance Rights are held, or the Board otherwise agrees.

There is no consideration payable by the holder upon the exercise of Performance Rights, and the Company must issue the relevant number of Shares to the holder of the Performance Rights, update its share register and issue and send to the holder an updated holding statement within 10 Business Days after receiving the Notice of Exercise.

6. Shares issued on exercise

The Share issued upon exercise of the Performance Rights will rank equally in all respects with the Company's ordinary shares and the Company will apply to the ASX for official quotation of the Shares after they are issued.

7. Shareholder and regulatory approvals

The grant and exercise of Performance Rights is subject to the Company obtaining all required consents and approvals. If the exercise of the Performance Rights would result in any person being in contravention of section 606(1) of the Corporations Act then the exercise of each

For personal use only



Performance Right that would cause the contravention will be deferred until such time or times that the exercise would not result in a contravention of section 606(1) of the Corporations Act. Holders must give notification to the Company in writing if they consider that the exercise of the Performance Rights may result in the contravention of section 606(1) of the Corporations Act, failing which the Company will be entitled to assume that the exercise of the Performance Rights will not result in any person being in contravention of section 606(1) of the Corporations Act.

8. **Participation in new issues**

There are no participation rights or entitlements inherent in the Performance Rights and holders will not be entitled to participate in new issues of capital offered to shareholders during the currency of the Performance Rights, including by way of bonus issue, rights issue or otherwise.

9. **Adjustment for bonus issues of Shares**

If the Company makes a bonus issue of Shares or other securities to existing Shareholders (other than an issue in lieu or in satisfaction of dividends or by way of dividend reinvestment) the number of Shares which must be issued on the exercise of the Performance Rights will be increased by the number of Shares which the holder would have received if the holder had exercised the Performance Rights before the record date for the bonus issue.

10. **Adjustment for rights issue**

If the Company makes a rights issue of Shares pro rata to existing Shareholders there will be no adjustment to the number of Performance Rights, or Shares to be issued upon the exercise of the Performance Rights.

11. **Adjustments for reorganisation**

If there is any reconstruction of the issued share capital of the Company, the rights of the holders may be varied to comply with the Listing Rules which apply to the reconstruction at the time of the reconstruction.

12. **Quotation**

The Company will not apply for quotation of the Performance Rights on ASX, but will apply for quotation of the Shares issued upon exercise of the Performance Rights.

13. **Transferability**

Performance Rights are only transferable in special circumstances (i.e. death or total or permanent disability, severe financial hardship or serious illness or injury) with the consent of the Board (which may be withheld in its absolute discretion).

14. **Compliance with laws**

If the Corporations Act, the Listing Rules or the Constitution conflicts with these terms and conditions, or these terms and conditions do not comply with the Corporations Act, the Listing Rules or the Constitution, the holder authorises the Company to do anything necessary to rectify such conflict or non-compliance, including but not limited to unilaterally amending these terms and conditions.

For personal use only

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity: AURORA LABS LIMITED
ABN 44 601 164 505

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	David James Budge
Date of last notice	30 August 2018

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Registered Holder: David James Budge ATF <Budge Family Trust> Relevant interest: Trustee & beneficiary
Date of change	30 November 2018
No. of securities held prior to change	<ol style="list-style-type: none"> 1. 23,946,785 Ordinary Shares 2. 725,000 Options (Ex \$0.20/Exp 31/12/2018) 3. 5,341,975 Class C Performance Shares 4. 115,000 Options (Ex \$2.23/ Exp 30/11/2019) 5. 165,000 Options (Ex \$3.00/ Exp 31/03/2020) 6. 15,000 Options (Ex \$0.79/ Exp 31/08/2020)
Class	<ol style="list-style-type: none"> 1. Ordinary Shares 2. Unquoted Options (Ex\$0.20/ Expiry 31/12/2018) 3. Class C Performance Shares 4. Unquoted Options (Ex \$2.23/Expiry 30/11/2019) 5. Unquoted Options (Ex \$3.00/Expiry 31/3/2020) 6. Unquoted Options (Ex \$0.79/Expiry 31/8/2020) 7. Performance Rights (Expiry 31 January 2023)

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

Number acquired	7. 50,000 Performance Rights
Number disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$0.752 per Performance Right (Refer to Valuation in Notice of Meeting for AGM dated 23 October 2018 at page 14)
No. of securities held after change	<ol style="list-style-type: none"> 1. 23,946,785 Ordinary Shares 2. 725,000 Options (Ex \$0.20/Exp 31/12/2018) 3. 5,341,975 Class C Performance Shares 4. 115,000 Options (Ex \$2.23/ Exp 30/11/2019) 5. 165,000 Options (Ex \$3.00/ Exp 31/03/2020) 6. 15,000 Options (Ex \$0.79/ Exp 31/08/2020) 7. 50,000 Performance Rights (Exp 31/01/2013)
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Issue of Performance Rights pursuant to Employee Incentive Plan and as approved by shareholders at AGM on 30/11/2018.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
Interest acquired	
Interest disposed	

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity: AURORA LABS LIMITED
ABN: 44 601 164 505

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	John Nathan Henry
Date of last notice	30 August 2018

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect & Direct
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Registered Holder: Buttes Pty Ltd <Toklat A/C> Relevant interest: Director
Date of change	30 November 2018
No. of securities held prior to change	<u>Direct</u> 1. 832,151 Ordinary Shares 2. 1,693,334 Unquoted Options (Ex \$0.20/ Expiry 31/12/2018) 3. 185,634 Class C Performance Shares <u>Indirect</u> 1. 150,000 Ordinary Shares 4. 140,000 Unquoted Options (Ex \$2.23/Expiry 30/11/2019) 5. 125,000 Unquoted Options (Ex \$3.00/Expiry 31/3/2020) 6. 15,000 Unquoted Options (Ex \$0.79/Expiry 31/08/2020)

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

Class	<ol style="list-style-type: none"> 1. Ordinary Shares 2. Unquoted Options (Ex\$0.20/ Expiry 31/12/2018) 3. Class C Performance Shares 4. Unquoted Options (Ex \$2.23/Expiry 30/11/2019) 5. Unquoted Options (Ex \$3.00/Expiry 31/3/2020) 6. Unquoted Options (Ex \$0.79/Expiry 31/8/2020) 7. Performance Rights (Expiry 31 January 2023)
Number acquired	7. 50,000 Performance Rights
Number disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$0.752 per Performance Right (Refer to Valuation in Notice of Meeting for AGM dated 23 October 2018 at page 14)
No. of securities held after change	<u>Direct</u> <ol style="list-style-type: none"> 1. 832,151 Ordinary Shares 2. 1,693,334 Options (Ex \$0.20/Exp 31/12/2018) 3. 185,634 Class C Performance Shares <u>Indirect</u> <ol style="list-style-type: none"> 1. 150,000 Ordinary Shares 4. 140,000 Options (Ex \$2.23/ Exp 30/11/2019) 5. 125,000 Options (Ex \$3.00/Exp 31/03/2020) 6. 15,000 Unquoted Options (Ex \$0.79/Expiry 31/08/2020) 7. 50,000 Performance Rights (Exp 31/01/2013)
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Issue of Performance Rights pursuant to Employee Incentive Plan and as approved by shareholders at AGM on 30/11/2018.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
---------------------------	-----

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
Interest acquired	
Interest disposed	
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
Interest after change	

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.

For personal use only

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity: AURORA LABS LIMITED
ABN 44 601 164 505

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Paul Kristensen
Date of last notice	30 August 2018

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Registered Holder: Capital Technologies Pty Ltd Relevant Interest: Mr Kristensen is a Director
Date of change	30 November 2018
No. of securities held prior to change	1. 100,000 Unquoted Options (Ex \$1.08/ Expiry 31/01/2021)
Class	1. Unquoted Options (Ex \$1.08/Expiry 31/1/2021) 2. Performance Rights (Expiry 31 January 2023)
Number acquired	2. 50,000 Performance Rights
Number disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$0.752 per Performance Right (Refer to Valuation in Notice of Meeting for AGM dated 23 October 2018 at page 14)

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

No. of securities held after change	1. 100,000 Unquoted Options (Ex \$1.08/ Expiry 31/01/2021) 2. 50,000 Performance Rights (Exp 31/01/2013)
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of Performance Rights pursuant to Employee Incentive Plan and as approved by shareholders at AGM on 30/11/2018.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.

For personal use only

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity: AURORA LABS LIMITED
ABN 44 601 164 505

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mel Ashton
Date of last notice	30 August 2018

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Registered Holder: Palms on Farms ATF <The Ashton Trust> Relevant Interest: Mr Ashton is a Beneficiary
Date of change	30 November 2018
No. of securities held prior to change	1. 50,000 Ordinary Shares 2. 100,000 Unquoted Options (Ex \$1.08/ Expiry 31/01/2021)
Class	1. Ordinary Shares 2. Unquoted Options (Ex \$1.08/Expiry 31/1/2021) 3. Performance Rights (Expiry 31 January 2023)
Number acquired	3. 50,000 Performance Rights
Number disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$0.752 per Performance Right (Refer to Valuation in Notice of Meeting for AGM dated 23 October 2018 at page 14)

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

No. of securities held after change	<ol style="list-style-type: none"> 1. 50,000 Ordinary Shares 2. 100,000 Unquoted Options (Ex \$1.08/ Expiry 31/01/2021) 3. 50,000 Performance Rights (Exp 31/01/2013)
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Issue of Performance Rights pursuant to Employee Incentive Plan and as approved by shareholders at AGM on 30/11/2018.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
Interest acquired	
Interest disposed	
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
Interest after change	

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity: AURORA LABS LIMITED
ABN 44 601 164 505

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mathew Whyte
Date of last notice	30 August 2018

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (j) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Registered Holder: Mr Mathew Joseph Whyte and Mrs Sarah Louise Whyte <M&S Whyte Family A/C> Relevant Interest: Mr Whyte is a trustee and beneficiary
Date of change	30 November 2018
No. of securities held prior to change	<ol style="list-style-type: none"> 1. 50,000 Unquoted Options (Ex \$3.00/Expiry 31/3/2020) 2. 15,000 Options (Ex \$0.079/ Exp 31/08/2020) 3. 100,000 Unquoted Options (Ex \$0.95/ Expiry 31/07/2020)
Class	<ol style="list-style-type: none"> 1. Unquoted Options (Ex \$3.00/Expiry 31/3/2020) 2. Unquoted Options (Ex \$0.79/Expiry 31/8/2020) 3. Unquoted Options (Ex \$0.95/ Expiry 31/7/2020) 4. Performance Rights (Expiry 31 January 2023)

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

Number acquired	4. 50,000 Performance Rights
Number disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$0.752 per Performance Right (Refer to Valuation in Notice of Meeting for AGM dated 23 October 2018 at page 14)
No. of securities held after change	<ol style="list-style-type: none"> 1. 50,000 Options (Ex \$3.00/ Exp 31/03/2020) 2. 15,000 Options (Ex \$0.079/ Exp 31/08/2020) 3. 100,000 Unquoted Options (Ex \$0.95/ Expiry 31/07/2020) 4. 50,000 Performance Rights (Exp 31/01/2013)
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Issue of Performance Rights pursuant to Employee Incentive Plan and as approved by shareholders at AGM on 30/11/2018.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
Interest acquired	

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.

For personal use only